Default company panoramic image
Logo

ReQuisite Biomedical

Next generation coatings for endovascular devices that leverage the pro-healing and non-toxic properties of resveratrol and quercetin.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Minneapolis, MN, USA
  • Currency USD
  • Founded January 2009
  • Employees 1
  • Website requisitebiomed.com

Company Summary

ReQuisite Biomedical is developing intravascular medical device coatings containing a combination of the natural compounds found in red wine - resveratrol and quercetin. The two compounds act in synergy to prevent negative responses to angioplasty treatment that cause re-narrowing of the arteries following a clinical intervention. The product pipeline will cover multiple categories of endovascular devices.

Team

  • Default avatar
    Margaret E Groh, PhD, MBA
    CEO

    Dr. Groh is an experienced biotechnology and medical device business development consultant. She spent six years at BioEnterprise, a venture development firm. Her experience includes fundraising, strategic planning, hiring and managing a team of analysts, and grant/business plan writing. She holds a PhD in Molecular Medicine from the University of Chicago and an MBA from Weatherhead School of Management.

  • Default avatar
    John D Foley, PhD
    Co-Founder

    Dr. Foley is a Cell and Molecular Biologist with experience in both academia and the medical device industry. He has broad background in medical device coatings for a range of applications (DES, anti-infectives, lubricity, etc.). He is currently Senior Manager of Research at Synovis Life Technologies, a division of Baxter BioSurgery.

  • Default avatar
    Tammy R Dugas, PhD
    Co-Founder

    Dr. Dugas is an Associate Professor in the Department of Pharmacology, Toxicology and Neuroscience at Louisiana State University Health Sciences Center - Shreveport where she conducts research aimed at the discovery of novel therapies for vascular diseases including atherosclerosis and restenosis. She is also Co-Director of the Pharmacology Core for a Feist Weiller Cancer Center group charged with developing new cancer therapeutics.

  • Default avatar
    Meghan E Lund, MS
    Co-Founder

    Ms. Lund was Project Manager at Nanocopoeia, Inc. responsible for the implementation and optimization of the ElectroNanosprayTM process for drug delivery applications. Before joining Nanocopoeia, she was a process development engineer with Boston Scientific Corporation where she worked on next generation stent coatings for Taxus® and Promus® DES products. She holds a M.S. in Chemical Engineering from the University of Cincinnati.